Slide 1: Company presentation
Company presentation Stockholm Corporate Finance, 12 march -20 Jonas Jarvius, PhD, CEO & President Co-founder STRICTLY PRIVATE AND CONFIDENTIAL
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS
Slide 3: Q-linea in brief
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea in brief Introduction to the company Introduction to the company • Q-linea is developing disruptive solutions for Lead product ASTar faster infectious disease diagnostics • Q-linea entered global partnership with Thermo F
Slide 4: Combating our times most urgent healthcare problem - sepsis
Combating our times most urgent healthcare problem - sepsis Sepsis is the leading cause of death in U.S. hospitals1), killing >500,000 people yearly in the EU and US2) Sepsis is also the #1 hospitalization cost in the US with over $24bn yearly3) Mortality increases 7.6% for every hour of delayed tre
Slide 5: Q-linea provides rapid actionable results in sepsis diagnosis
Q-linea provides rapid actionable results in sepsis diagnosis Identification analysis (ID) – “What bug” Source: Company • To determine identity of information. the causative pathogen e.g. E. coli bacteria ASTar • And if applicable determine the presence of resistance genes e.g. MecA (expressed by ma
Slide 6: More than hours faster actionable results with ASTar
More than 24 hours faster actionable results with ASTar ILLUSTRATIVE DAY 1 D AY 2 D AY 3 D AY 4 Plates are streaked Current workflow Gram Susceptibility Patient to perform a Colony stain Determination blood draw clean culture selection (AST) Blood bottle Rapid ID Optimized Overnight 0.5 McFarland in
Slide 7: Health economic benefits of 24h faster AST on septic patients
Health economic benefits of 24h faster AST on septic patients Rapid and efficient solution results in significant health economic benefits Less pressure for Lower mortality resistance and Decreased length of superinfections stay and reduced severity Up to 25%3) Up to 40% reduction of C. difficile in
Slide 8: Q-linea's lead product candidate ASTar – a modular AST system
Q-linea’s lead product candidate ASTar – a modular AST system • Phenotypic AST results in 3 to 6 hours ASTar offering Rapid for blood System • Answer <45 minutes for e.g. urine • Fully automated Simple to use • Up to 12 samples analysed in parallel • Up to 50 samples per day Consumables Fully-automa
Slide 9: Excellent and accurate data from over 3700 bug-drug combinations
Excellent and accurate data from over 3700 bug-drug combinations Technology proven on positive blood culture bottles AST data summaryFDA and ISO requirements1,2) • Extensively tested on clinically relevant pathogens in Essential agreement = Same as reference correct sample matrix ✓ Over 270 differen
Slide 10: The AST market, ASTar is designed to handle any sample & workflow
The AST market, ASTar is designed to handle any sample & workflow Rapid AST Traditional isolate AST Semi-automated workflow Semi-automated workflow Fully-automated workflow User is required to perform sample User is required to perform sample Less than 1 minutes hands-on time preparation preparation
Slide 11: Large addressable market for rapid AST diagnostics instruments
Large addressable market for rapid AST diagnostics instruments ASTar® has several potential target markets Number of Antimicrobial Susceptibility Tests for in vitro diagnostics Sepsis LRTI Positive blood Respiratory BAL´s1) cultures 1) 1.6M 17,4M Complicated UTI´s Urine tests 2) 10,9M Outpatient's &
Slide 12: A few large hospitals accounts for the majority of blood cultures
A few large hospitals accounts for the majority of blood cultures BC sets taken per hospital category (by discharges) in USA 4500 50000 4170 Q-linea primary customers 45000 4000 40000 Very large 3500 No hospitals/discharge category 35000 3000 No of BC sets 2500 30000 93% 25000 2000 Large 20000 1500
Slide 13: ASTar key highlights & value proposition
ASTar key highlights & value proposition Disruptive AST analysis 1 Broad panel coverage Enables both escalation & de-escalation Minimize need for follow-up tests required 2 Broad pathogen coverage Includes both fastidious & non-fastidious bacteria 3 High throughput & Random access Up to 50 patient s
Slide 14: Go-to-market strategy with strategic sales partner
Go-to-market strategy with strategic sales partner • We share the view on how to improve and what is Common vision needed to change future infectious disease dx. • Global and local reach Gain market access • Strong customer relationships quickly • Access to large organizations immediately • Strong b
Slide 15: Key activities for upcoming launch of ASTar
Key activities for upcoming launch of ASTar Achievements Future key events US study design Opening of new 2019 approved by the FDA consumable production facility in Uppsala ASTar passes EMC (ElectroMagnetic Market presentation of Compatibility) ASTar at ECCMID, Paris testing Start of clinical trials